Preparation of stable solid lipid nanoparticles (SLNs) suspension with combined surfactants

Journal of China Pharmaceutical University

Volumn 36, Issue 5, 2005, Pages 417-422

  Hou, Dong Zhi ^a,b   Xie, Chang Sheng ^a   Ping, Qi Neng ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Solid lipid nanoparticles (SLNs); Surfactant mixture; Zeta potential

Indexed keywords

DEOXYCHOLATE SODIUM; EMULSIFYING AGENT; IONIC SURFACTANT; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; SURFACTANT;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; LASER DIFFRACTION; NANOTECHNOLOGY; PARTICLE SIZE; PHYSICAL CHEMISTRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 27744448702     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Müller RH, Mehnert W, Lucks JS. Solid lipid nanoparticles (SLN) - an alternative colloidal carrier system for controlled drug delivery [J]. Eur J Pharm Biopharm, 1995,41(1):62-71.
2. Mizushima Y. Lipid microspheres (lipid emulsions) as a drug carrier - an overview [J]. Adv Drug Del Rev, 1996,20(2-3):113-123.
3. Scholer N, Olbrich C, Müller RH. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages [J]. Int J Pharm, 2001,221(1):57-65.
4. Freitas C, Müller RH. Statibility determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte [J]. J Microencapsulation, 1999,16(1):59-67.
5. Hou DZ, Xie CS, Huang KJ, et al. The production and characteristics of solid lipid nanoparticles (SLNs) [J]. Biomaterials, 2003,24(4): 1 781-1 787.
6. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future [J]. Adv Drug Deliv Rev, 2001,47(1):3-15.
7. Müller RH, Bohm BHL. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs [M]. Stuttgart: Medpharm Scientific, 1998.149.
8. Zimmermann E, Müller RH. Electrolyte-and pH-stabilities of aqueous solid lipid nanoparticles (SLN™) dispersions in artificial gastrointestinal media [J]. Eur J Pharm Biopharm, 2001,52(2):203-215.
9. Riddick TM. Zeta-meter Manual [M]. Zeta, New York. 1968.
10. Gasco MR. Method for producing solid lipid microsphere having a narrow size distribution [P]. US Patent, 5250236.1993.
11. Tadras TF, Vincent B. Influence of temperature and electrolytes on the adsorption of poly(ethylene oxide)-poly(propylene oxide) block copolymer on polystyrene latex and on the stability of the polymer coated particles [J]. J Phys Chem, 1980,84(8):1 575-1582.
12. Reich G. In vitro stability of poly (D, L-lactide) and poly (D, L-lactide)/poloxamer nanoparticles in gastrointestinal fluids [J]. Drug Dev Ind Pharm, 1997,23(6):1 191-1 198.
13. Dekker M. Phospholipid Handbook [M]. Cevc G(Ed.), New York, 1993.156.
14. Ishington C. Stability of lipid emulsions for drug delivery [J]. Adv Drug Deliv Rev, 1996,20(2):131-141.
15. Hunter RH. Foundation of Colloid Science [M]. Oxford University Press Oxford, 1986.268.
16. Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase [J]. Eur J Pharm Biopharm, 1999,47(3):125-131.